Anti-Craving Drugs for Alcohol Use Disorder (AUD)

FDA-Approved First-Line Agents

1. Naltrexone (ReVia / Vivitrol)

• Dose: 50 mg/day orally, OR 380 mg IM every 4 weeks (extended-release injectable - Vivitrol)
• Evidence: The landmark COMBINE study demonstrated that naltrexone improves clinical outcomes; a Cochrane review confirmed it reduces heavy drinking days.
• Side effects: Mild GI upset, lethargy, nausea
• Note: Contraindicated in active opioid use or opioid dependence (will precipitate withdrawal). Extended-release IM form improves compliance significantly.
• Best for: Patients who want to cut down or abstain, especially "reward drinkers" who drink for the euphoric effect.

2. Acamprosate (Campral)

• Dose: ~2,000 mg/day divided into 3 doses (666 mg TID)
• Evidence: Moderate efficacy in clinical trials; works best when the patient is already abstinent at the start of treatment.
• Side effects: Primarily GI (diarrhea) - relatively mild.
• Contraindication: Severe renal impairment (renally excreted).
• Best for: Patients already abstinent who want to maintain abstinence and reduce anxiety/sleep disturbances from protracted withdrawal.

3. Disulfiram (Antabuse)

• Dose: 250 mg/day
• Evidence: Limited efficacy because patients simply stop taking it before drinking. Most effective when supervised (e.g., partner or clinician watches ingestion).
• Dangers: Mood swings, rare psychosis, peripheral neuropathy, hepatotoxicity (potentially fatal hepatitis)
• Contraindications: Heart disease, cerebral thrombosis, diabetes (reaction could be fatal)
• Best for: Highly motivated patients who want a pharmacological "guardrail" to prevent impulsive drinking.

Off-Label but Clinically Used Agents

4. Gabapentin

• Reduces alcohol craving and withdrawal symptoms, especially in patients with a history of alcohol withdrawal syndrome
• Dose ~1800 mg/day showed increased abstinence rates and reduced binge drinking in trials
• Particularly useful for patients with comorbid anxiety or pain
• Caution: Abuse potential in some patients; used cautiously
• Referenced in Goodman & Gilman's and GOLDMAN-CECIL Medicine

5. Topiramate

• Anticonvulsant (fructopyranose derivative) that modulates glutamate and GABA
• Effective at up to 300 mg/day for reducing alcohol dependence
• Titrate slowly to reduce cognitive side effects (word-finding difficulty)
• Supported by Harrison's (22nd ed.) and multiple controlled trials

6. Baclofen

• GABA-B receptor agonist; reduces craving especially in anxious patients
• Some evidence from European trials; less used in the US
• May be particularly helpful in patients with liver disease (unlike naltrexone)

7. Ondansetron (5-HT3 antagonist)

• Some evidence particularly in early-onset alcoholism (before age 25)
• May reduce craving through serotonergic modulation
• Not widely adopted as first-line

8. Varenicline (Chantix)

• Primarily a smoking cessation drug (partial nicotinic agonist)
• Studies show it can reduce binge drinking; useful in patients with comorbid alcohol and tobacco use
• Referenced in Harrison's 22E (2025) and Katzung's 16th Edition

9. Prazosin (alpha-1 adrenergic blocker)

• Especially useful in combination with naltrexone
• Some evidence for reducing stress-induced craving (referenced in Harrison's 22E)

Which Drug to Choose?

Combination Therapy

• Kaplan & Sadock's Synopsis of Psychiatry, p. 896
• Kaplan & Sadock's Comprehensive Textbook of Psychiatry - Alcoholism section
• Harrison's Principles of Internal Medicine 22E (2025) - Rehabilitation phase
• Goodman & Gilman's Pharmacological Basis of Therapeutics
• Goldman-Cecil Medicine - Other Pharmacologic Approaches
• Katzung's Basic and Clinical Pharmacology, 16th ed.
• Systematic review: anti-craving medications in ED settings, PMID 37735346 (Acad Emerg Med 2024)

Clinical note: All pharmacotherapy for AUD is most effective when combined with behavioral interventions (CBT, motivational enhancement, AA/12-step programs). Medications alone without psychosocial support have limited long-term efficacy.